Press Releases

26 Jun 2018

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

read more ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

download PDF

24 May 2018

ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

read more ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

download PDF

18 Apr 2018

ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

read more ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

download PDF

08 Mar 2018

ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

read more ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

download PDF

07 Feb 2018

ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology

read more ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology

download PDF

05 Oct 2017

Chiome Bioscience Selects ProBioGen for GlymaxX® Antibody Manufacturing Program

read more Chiome Bioscience Selects ProBioGen for GlymaxX® Antibody Manufacturing Program

download PDF

15 Jun 2017

ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

read more ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

download PDF

01 Jun 2016

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

read more Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

download PDF

18 May 2016

ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics

read more ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics

download PDF

19 Apr 2016

ProBioGen And Eucodis Sign Agreement to Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

read more ProBioGen And Eucodis Sign Agreement to Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

download PDF

Page 2 of 7

Previous
1
2
3
4
5
6
7
Next
Last »